BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 7878650)

  • 1. Viral safety and clotting factor concentrates.
    Laurian Y; Lusher JM; Kessler CM
    Thromb Haemost; 1994 Oct; 72(4):649. PubMed ID: 7878650
    [No Abstract]   [Full Text] [Related]  

  • 2. Viral safety of clotting factor concentrates.
    Fricke WA; Lamb MA
    Semin Thromb Hemost; 1993; 19(1):54-61. PubMed ID: 8456324
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Virus safety of pasteurized clotting factor concentrates.
    Kreuz W; Becker S; Auerswald G; Kurnick K; Kröniger A; Klarmann D
    Semin Thromb Hemost; 2002 Apr; 28 Suppl 1():57-62. PubMed ID: 12016580
    [No Abstract]   [Full Text] [Related]  

  • 4. Virus infection and clotting factor concentrates.
    Rubinstein DB
    Lancet; 1995 May; 345(8959):1248. PubMed ID: 7739339
    [No Abstract]   [Full Text] [Related]  

  • 5. Laboratory and preclinical evaluation of the virus safety of coagulation factor concentrates.
    Horowitz B; Prince AM
    Dev Biol Stand; 1987; 67():291-302. PubMed ID: 3609483
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Virus in hemophilia: current status and future perspectives].
    Aguilar C; Félix Lucía J
    Sangre (Barc); 1996 Apr; 41(2):141-5. PubMed ID: 9045355
    [No Abstract]   [Full Text] [Related]  

  • 7. Sixteen years of treatment with pasteurized human clotting factor concentrates in children and adolescents: a pharmacosurveillance investigation comprising 727 patient years.
    Muntean W; Zenz W; Falger J; Male C; Streif W; Wank J; Schwarz R; Schmitt K; Kurnik P; Zwiauer K
    Semin Thromb Hemost; 2002 Apr; 28 Suppl 1():63-74. PubMed ID: 12016581
    [No Abstract]   [Full Text] [Related]  

  • 8. Virus infection and clotting factor concentrates.
    Evans DI
    Lancet; 1995 May; 345(8959):1247-8. PubMed ID: 7739337
    [No Abstract]   [Full Text] [Related]  

  • 9. Safety aspects in the manufacturing of plasma-derived coagulation factor concentrates.
    Burnouf T
    Biologicals; 1992 Jun; 20(2):91-100. PubMed ID: 1389114
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of the risk of hepatitis from clotting factor concentrates.
    Fricke WA
    Prog Clin Biol Res; 1990; 324():161-6. PubMed ID: 2408051
    [No Abstract]   [Full Text] [Related]  

  • 11. Current safety of clotting factor concentrates.
    Foster PR; McIntosh RV
    Arch Pathol Lab Med; 1990 Dec; 114(12):1188-9. PubMed ID: 2123621
    [No Abstract]   [Full Text] [Related]  

  • 12. Viral safety of solvent-detergent treated blood products.
    Horowitz B; Prince AM; Horowitz MS; Watklevicz C
    Dev Biol Stand; 1993; 81():147-61. PubMed ID: 8174797
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Frequency of contamination of coagulation factor concentrates with novel human parvovirus PARV4.
    Schneider B; Fryer JF; Oldenburg J; Brackmann HH; Baylis SA; Eis-Hübinger AM
    Haemophilia; 2008 Sep; 14(5):978-86. PubMed ID: 18565125
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Viral safety of plasma-derived factor VIII and IX concentrates.
    Ludlam CA
    Blood Coagul Fibrinolysis; 1997 Aug; 8 Suppl 1():S19-23. PubMed ID: 9351532
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Transfusion-transmitted disease.
    Lee CA
    Baillieres Clin Haematol; 1996 Jun; 9(2):369-94. PubMed ID: 8800511
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Viral safety of recombinant factor IX.
    Adamson S; Charlebois T; O'Connell B; Foster W
    Semin Hematol; 1998 Apr; 35(2 Suppl 2):22-7. PubMed ID: 9565163
    [TBL] [Abstract][Full Text] [Related]  

  • 17. FDA perspective on and response to the risk of hepatitis A from blood products.
    Fricke W
    Vox Sang; 1994; 67 Suppl 4():16-8; discussion 24-6. PubMed ID: 7831864
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Quality control in the development of coagulation factor concentrates.
    Snape TJ
    Dev Biol Stand; 1987; 67():141-7. PubMed ID: 3609474
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Interim results of surveillance for NANBH in patients receiving heated concentrates produced in England.
    Smith JK; Winkelman L; Feldman PA
    Dev Biol Stand; 1987; 67():323-5. PubMed ID: 3111910
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of GB virus C, HIV, and HCV infection markers in hemophiliacs exposed to non-inactivated or inactivated factor concentrates.
    Kupfer B; Ruf T; Matz B; Nattermann J; Spengler U; Rockstroh JK; Brackmann HH; Blümel J; Tacke M; Kaiser R
    J Clin Virol; 2005 Sep; 34(1):42-7. PubMed ID: 16087123
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.